Prior to his retirement in June 2024 from his operational role, David Dally joined Engitix as Chief Financial Officer (CFO) in November 2018, having initially worked for the company as a consultant from 2016.

David has 30 years' experience in the biotech and pharmaceutical industry, working in finance and general management across companies of varying size, financial ownership and geographical location, including in the UK, the US and Asia.

David is an experienced executive having held the position of CEO at MerLion Pharmaceuticals from 2013 to 2018, before which he was CFO from 2007.

During his career, David has been CFO for several companies including KuDOS Pharmaceuticals (which was sold to AstraZeneca for $210 million), Rhytec Ltd, and Dyson. He established his career as a financial leader through various roles at Amersham plc (now GE Healthcare), latterly as Vice President of finance, North America where he oversaw the merger of Amersham Life Science with Pharmacia Biotech.

David is a chartered accountant and holds a MA in Geography from the University of Cambridge.